Categories for COVID-19/Coronavirus



Lonza and Moderna Announce Further Collaboration For Drug Substance Manufacturing of COVID-19 Vaccine Moderna in the Netherlands

Lonza today announced the expansion of its collaboration with Moderna, a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines. The expanded collaboration will further extend the manufacture of the drug substance for the COVID-19 Vaccine Moderna and provides for the installation of a new manufacturing line for drug substance production at Lonza’s Geleen (NL) site.

June 2, 2021


Best Practices and Considerations for Developing Vaccine Policy in the Specialty Chemical Industry

As SOCMA continues to keep a pulse on the specialty and fine chemical industry, we understand that companies across the industry are grappling with how to encourage employee inoculations now that there’s increased availability of COVID-19 vaccines. We’ve spoken with leaders from Texas to Rhode Island and everywhere in between about how they are handling the vaccination within their companies, and here are a few takeaways you can consider when implementing your own plans.

March 22, 2021


SOCMA Policy Blog

SOCMA has identified two EOs that will intersect with the work and activities of its Environmental, Health and Safety committee. Alongside our members, we are prepared to further our advocacy efforts through each agency's review and decision process.

January 27, 2021

Capricor Collaborates with Lonza for the Development of CAP-1002, its Cell Therapy Candidate for the Treatment of Duchenne Muscular Dystrophy and Other Indications

Capricor Therapeutics, a clinical-stage biotechnology company focused on the development of the first-in-class cell and exosome-based therapeutics for the treatment and prevention of serious diseases, and Lonza today announced that the companies have entered into an agreement for the development of CAP-1002, Capricor's leading clinical asset using allogeneic cardiosphere-derived cells (CDC) technology for the treatment of Duchenne Muscular Dystrophy (DMD) and complications arising from COVID-19.

January 12, 2021



Humanigen and Lonza Announce Collaboration to Expand Manufacturing of Humanigen’s COVID-19 Therapeutic Candidate Lenzilumab

Humanigen, a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper response called ‘cytokine storm,’ and Lonza today announced a strategic collaboration to expand the manufacturing capacity for lenzilumab, currently in Phase 3 clinical trials for COVID-19, in advance of potential Emergency Use Authorization in 2020 and subsequent commercialization.

September 16, 2020